📊 CPRX Key Takeaways
Is Catalyst Pharmaceuticals, Inc.. (CPRX) a Good Investment?
Catalyst Pharmaceuticals demonstrates exceptional fundamental strength with 49% operating margins, 19.8% YoY revenue growth, and 28.2% EPS growth, supported by a fortress balance sheet with $755.9M cash and zero debt. The capital-light business model with minimal CapEx generates strong 39.9% FCF margin, though the company must demonstrate effective capital deployment and sustainable competitive advantages in a competitive pharmaceutical landscape.
Catalyst Pharmaceuticals shows strong fundamental quality with nearly 20% revenue growth, very high operating and net margins, and exceptional free cash flow generation. The balance sheet is unusually strong for a pharmaceutical company, with substantial cash, no meaningful leverage, and ample liquidity. The main caution is that net income was flat despite higher revenue, which suggests profit growth may be moderating and should be monitored for sustainability.
Catalyst Pharmaceuticals, Inc.. Key Strengths (CPRX)
- Exceptional profitability: 49% operating margin and 42.7% net margin indicate highly competitive products with substantial pricing power
- Dual growth acceleration: 19.8% YoY revenue growth coupled with 28.2% EPS growth demonstrates profitable expansion and shareholder value creation
- Fortress balance sheet: $755.9M cash, zero long-term debt (0.00x Debt/Equity), and 7.10x current ratio provide strategic flexibility and financial resilience
- Capital-light model: Minimal CapEx ($27K) with $59.6M operating cash flow generates 39.9% FCF margin, indicating highly efficient capital structure
- Strong liquidity: 6.84x quick ratio enables weather market disruptions and fund growth without leverage
- High profitability with 43.8% operating margin and 36.4% net margin
- Excellent financial health with $709.17M in cash, 6.08x current ratio, and no meaningful debt
- Strong cash generation with $208.61M of free cash flow and a 35.4% FCF margin
CPRX Stock Risks: Catalyst Pharmaceuticals, Inc.. Investment Risks
- Capital deployment inefficiency: 6.3% ROE and 5.6% ROA despite exceptional margins suggest excess cash may not be optimally deployed
- Pharmaceutical sector risks: Patent cliffs, regulatory changes, clinical trial failures, and reimbursement pressures threaten revenue sustainability
- Product concentration risk: Pharma companies typically depend on limited blockbuster drugs, creating revenue volatility risk if single product faces headwinds
- Limited insider activity and visibility: One Form 4 filing in 90 days provides minimal signal on management confidence or future strategic direction
- Cost structure opacity: Gross margin data unavailable limits assessment of production efficiency and pricing power sustainability
- Net income was flat year over year despite strong revenue growth, indicating possible margin or expense pressure
- Pharmaceutical fundamentals can be vulnerable to product concentration, reimbursement changes, and regulatory risk
- Return profile is strong now, but sustaining nearly 20% growth at current margin levels may become more difficult
Key Metrics to Watch
- Revenue growth trajectory: Monitor if 19.8% YoY growth sustains or slows, indicating market saturation or competitive pressure
- Operating margin trend: Track profitability erosion from competition, pricing pressure, or R&D investment increases
- Free cash flow generation: Verify $59.6M FCF is sustainable and recurring, not one-time benefit
- Capital allocation decisions: Monitor for dividend initiation, share buybacks, debt issuance, or M&A indicating cash deployment strategy
- Product pipeline maturity: Assess clinical trial outcomes and regulatory approvals driving future revenue beyond current blockbuster products
- Net income and operating margin trend versus revenue growth
- Free cash flow conversion and cash deployment discipline
Catalyst Pharmaceuticals, Inc.. (CPRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 39.9% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 7.10x current ratio provides a solid financial cushion.
CPRX Profit Margin, ROE & Profitability Analysis
CPRX vs Healthcare Sector: How Catalyst Pharmaceuticals, Inc.. Compares
How Catalyst Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Catalyst Pharmaceuticals, Inc.. Stock Overvalued? CPRX Valuation Analysis 2026
Based on fundamental analysis, Catalyst Pharmaceuticals, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Catalyst Pharmaceuticals, Inc.. Balance Sheet: CPRX Debt, Cash & Liquidity
CPRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Catalyst Pharmaceuticals, Inc..'s revenue has grown significantly by 318% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.63 reflects profitable operations.
CPRX Revenue Growth, EPS Growth & YoY Performance
CPRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $141.4M | $56.7M | $0.45 |
| Q3 2025 | $128.7M | $23.3M | $0.35 |
| Q2 2025 | $122.7M | $23.3M | $0.33 |
| Q1 2025 | $98.5M | $23.3M | $0.19 |
| Q3 2024 | $102.7M | $23.3M | $-0.29 |
| Q2 2024 | $99.6M | $23.3M | $0.33 |
| Q1 2024 | $85.4M | $23.3M | $0.19 |
| Q3 2023 | $57.2M | $13.2M | $0.20 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Catalyst Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
CPRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Catalyst Pharmaceuticals, Inc.. (CIK: 0001369568)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CPRX
What is the AI rating for CPRX?
Catalyst Pharmaceuticals, Inc.. (CPRX) has a Combined AI Grade of A from Claude (A) and ChatGPT (A) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CPRX's key strengths?
Claude: Exceptional profitability: 49% operating margin and 42.7% net margin indicate highly competitive products with substantial pricing power. Dual growth acceleration: 19.8% YoY revenue growth coupled with 28.2% EPS growth demonstrates profitable expansion and shareholder value creation. ChatGPT: High profitability with 43.8% operating margin and 36.4% net margin. Excellent financial health with $709.17M in cash, 6.08x current ratio, and no meaningful debt.
What are the risks of investing in CPRX?
Claude: Capital deployment inefficiency: 6.3% ROE and 5.6% ROA despite exceptional margins suggest excess cash may not be optimally deployed. Pharmaceutical sector risks: Patent cliffs, regulatory changes, clinical trial failures, and reimbursement pressures threaten revenue sustainability. ChatGPT: Net income was flat year over year despite strong revenue growth, indicating possible margin or expense pressure. Pharmaceutical fundamentals can be vulnerable to product concentration, reimbursement changes, and regulatory risk.
What is CPRX's revenue and growth?
Catalyst Pharmaceuticals, Inc.. reported revenue of $149.4M.
Does CPRX pay dividends?
Catalyst Pharmaceuticals, Inc.. does not currently pay dividends.
Where can I find CPRX SEC filings?
Official SEC filings for Catalyst Pharmaceuticals, Inc.. (CIK: 0001369568) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CPRX's EPS?
Catalyst Pharmaceuticals, Inc.. has a diluted EPS of $0.50.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CPRX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Catalyst Pharmaceuticals, Inc.. has a A grade with 78% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is CPRX stock overvalued or undervalued?
Valuation metrics for CPRX: ROE of 6.3% (sector avg: 15%), net margin of 42.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CPRX's AI grade for 2026?
Our dual AI analysis gives Catalyst Pharmaceuticals, Inc.. a combined A grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is CPRX's free cash flow?
Catalyst Pharmaceuticals, Inc..'s operating cash flow is $59.6M, with capital expenditures of $27.0K. FCF margin is 39.9%.
How does CPRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 42.7% (avg: 12%), ROE 6.3% (avg: 15%), current ratio 7.10 (avg: 2).